{
    "title": "Germany's Merck in fresh bid to enter U.S. MS pill market",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-5182593/Germanys-Merck-fresh-bid-enter-U-S-MS-pill-market.html",
    "date": "2017-12-15",
    "keywords": [
        "ms",
        "mavenclad",
        "market",
        "drug",
        "blockbuster",
        "development",
        "merck",
        "approval",
        "group",
        "burger",
        "treatment",
        "pill",
        "europe",
        "year",
        "cancer",
        "fda",
        "healthcare",
        "garijo",
        "term",
        "potential",
        "analyst",
        "product",
        "patient",
        "percent",
        "kgaa",
        "sclerosis",
        "side",
        "end",
        "cladribine",
        "august",
        "equipment",
        "food",
        "administration",
        "quarter",
        "head",
        "division",
        "belen",
        "opportunity",
        "growth",
        "franchise",
        "industry",
        "immunotherapy",
        "bavencio",
        "part",
        "business",
        "sale",
        "consumer",
        "unit",
        "thursday",
        "perrigo",
        "bid",
        "privateequity",
        "stada",
        "september",
        "union",
        "latecomer",
        "disease",
        "kapadia",
        "euros",
        "peak",
        "expectation",
        "hugo",
        "solvet",
        "account",
        "consensus",
        "company",
        "guidance",
        "type",
        "damage",
        "disability",
        "aspiration",
        "registration",
        "course",
        "label",
        "executive",
        "biogen",
        "novartis",
        "injection",
        "share",
        "infusion",
        "march",
        "ocrevus",
        "progressive",
        "amount",
        "baggage",
        "thomasson",
        "dale",
        "hudson"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}